Zimmer Biomet (ZBH) Earns Buy Rating from BMO Capital Markets
BMO Capital Markets restated their buy rating on shares of Zimmer Biomet (NYSE:ZBH) in a report issued on Tuesday morning. They currently have a $144.00 price target on the medical equipment provider’s stock.
ZBH has been the topic of several other reports. Royal Bank of Canada reduced their price target on Zimmer Biomet to $125.00 and set an outperform rating on the stock in a report on Tuesday, November 7th. Zacks Investment Research cut Zimmer Biomet from a hold rating to a sell rating in a report on Monday, November 6th. SunTrust Banks boosted their price target on Zimmer Biomet to $142.00 and gave the stock a buy rating in a report on Monday. Jefferies Group restated a buy rating and set a $136.00 price target on shares of Zimmer Biomet in a report on Friday, November 3rd. Finally, Canaccord Genuity restated a hold rating and set a $125.00 price target on shares of Zimmer Biomet in a report on Tuesday, December 19th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $141.67.
Shares of Zimmer Biomet (NYSE ZBH) opened at $128.19 on Tuesday. The firm has a market capitalization of $25,920.00, a PE ratio of 14.21, a PEG ratio of 1.97 and a beta of 1.15. The company has a debt-to-equity ratio of 0.76, a quick ratio of 0.78 and a current ratio of 1.52. Zimmer Biomet has a twelve month low of $108.03 and a twelve month high of $133.49.
The business also recently announced a quarterly dividend, which was paid on Monday, January 29th. Investors of record on Friday, December 29th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.75%. The ex-dividend date of this dividend was Thursday, December 28th. Zimmer Biomet’s payout ratio is presently 10.64%.
A number of hedge funds have recently made changes to their positions in ZBH. Bank of Nova Scotia Trust Co. bought a new stake in Zimmer Biomet in the third quarter valued at approximately $112,000. FNY Managed Accounts LLC bought a new position in shares of Zimmer Biomet during the 3rd quarter worth approximately $117,000. Cerebellum GP LLC bought a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $133,000. Steward Partners Investment Advisory LLC bought a new position in shares of Zimmer Biomet during the 3rd quarter worth approximately $140,000. Finally, BB&T Investment Services Inc. bought a new position in shares of Zimmer Biomet during the 2nd quarter worth approximately $144,000. Institutional investors and hedge funds own 86.20% of the company’s stock.
WARNING: This piece of content was reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/02/02/zimmer-biomet-zbh-earns-buy-rating-from-bmo-capital-markets.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.